Is BPC-157 Legal Now? The Category 2 Reversal

BPC-157 has quietly disappeared from the main table of the FDA's Category 2 list, the roster of nominated compounding ingredients the agency has flagged for significant safety risks. By 22 April 2026 the agency's own page had the compound filed somewhere else entirely; FDA publishes no date for the move itself. Three months after that page date, on 23 July 2026, a federal advisory committee spent a morning arguing over whether the same peptide should go onto the list pharmacies may lawfully compound from. Both events are documented on FDA's own pages, and both have been read online as the moment BPC-157 became legal. Neither one did that. BPC-157 is still not approved by the FDA for human use, and neither event made it lawful to sell for people. This page is the timeline, with the paperwork attached.^{[1, 3]}

What actually changed in April 2026

FDA's public Category 2 page no longer carries BPC-157 in its main table of substances the agency says may present significant safety risks. The compound now sits in a second table further down the same page, headed "Bulk drug substances nominated but withdrawn," which FDA describes as substances "previously in category 2 of the interim policies" that "were withdrawn by the nominators." That is the entire mechanism. The parties who filed the nominations pulled them; the agency did not re-run the science and decide its concerns had gone away. The proof sits on the same page, because FDA still publishes, word for word, the risk language it wrote for this compound: that compounded drugs containing BPC-157 "may pose risk for immunogenicity" by certain delivery routes, that peptide-related impurities and ingredient characterization are complex, and that the agency "lacks sufficient information to know whether the drug would cause harm" in people. The page carrying all of that was current as of 22 April 2026, which is after the change. A row moved. The safety view did not.^[1]

Off Category 2 is not on Category 1

FDA's interim compounding policy sorts nominated bulk substances into three buckets, and the gap between them is where most of the confusion lives. Category 1 covers substances that "may be eligible" for the 503A Bulks List and arrived with enough supporting information to evaluate; for those, FDA says it "does not intend to take action against a compounder" who uses them under the stated conditions. Category 2 covers substances the agency has flagged with significant safety risks, and it explicitly excludes them from that Category 1 posture. Category 3 covers nominations that arrived without enough information to evaluate at all. Leaving Category 2 does not put a substance into Category 1, and none of the three buckets is the 503A Bulks List itself. That list is a regulation, and FDA says it will address nominated substances for it "on a rolling basis through notice-and-comment rulemaking." A withdrawn nomination is simply out of the sorting system entirely: not flagged, not eligible, not approved, just gone from the queue.^[2]

What the July advisory committee actually voted on

On 23 and 24 July 2026 the FDA's Pharmacy Compounding Advisory Committee met to weigh seven peptide substances for the 503A Bulks List, and BPC-157 led the first morning. The published voting questions are narrow and worth reading literally: "Should BPC-157 (free base) be placed on the list?" and "Should BPC-157 acetate be placed on the list?" The free base and the acetate salt are different ingredients and were put to separate votes. FDA's meeting page also records the use its reviewers assessed: ulcerative colitis, a serious bowel disease. Not tendon recovery or gut repair, which is what most people searching this compound are actually asking about. FDA's own scientific review team arrived recommending against it: the agency's briefing document concludes the criteria "weigh against" both forms and states plainly, "we propose not adding BPC-157 (free base) or BPC-157 acetate to the 503A Bulks List." Press reports from the room put the committee's tally at 8–6 with one abstention in favour of inclusion, for each form; FDA had not published official minutes or a transcript when this page was last updated. A committee recommendation is advice. It does not change what is approved, and it does not amend the list on its own.^{[3, 4, 5]}

What still has to happen before a pharmacy can compound it

Even on the most generous reading of the July vote, several things stand between a show of hands and a lawful compounded product. FDA has said it addresses substances for the 503A Bulks List through notice-and-comment rulemaking, meaning a published proposed rule, a public comment window, then a final rule. Not an advisory vote. Until that runs its course, BPC-157 is not on the list, and it is not approved by the FDA for any human use. It is also worth being precise about what listing would and would not buy you. A compounded medicine is not an approved medicine: FDA states flatly that "compounded drugs are not FDA-approved," which means the agency "does not verify the safety, effectiveness or quality of compounded drugs before they are marketed." Adding an ingredient to the 503A Bulks List makes a prescription-only compounded preparation legally possible for a licensed pharmacy. It does not turn the compound into a reviewed, approved drug, and it does nothing at all for a research-use-only product bought online.^{[2, 6]}

What none of this changes: the research market and sport

The BPC-157 most people encounter is not a compounded prescription at all. It is a research chemical sold online under a "research use only, not for human consumption" label: a laboratory reagent, outside any regulator's quality check, with no requirement that the contents match what is printed on it. Nothing in the April page update or the July vote touches that market, and neither one makes those products approved or lawful to sell for people. Sport is a separate layer again, and it did not move either. The World Anti-Doping Agency names BPC-157 explicitly in class S0, non-approved substances, on the 2026 Prohibited List that came into effect on 1 January 2026, prohibited at all times, in and out of competition. WADA's own definition of that class is instructive, because it covers any pharmacological substance with no current approval by any government health authority for human therapeutic use. A tested athlete's exposure is unchanged by anything FDA's compounding lists do.^{[1, 7]}

The evidence underneath the paperwork

Strip away the regulatory drama and the human evidence base for BPC-157 is thin enough to fit in a paragraph. FDA's July briefing document reports that a literature search of PubMed and Embase turned up five clinical studies using BPC-157 at all, and that for effectiveness in ulcerative colitis there is exactly one randomised, double-blind, placebo-controlled study, published only as a conference abstract, with 53 people randomised and 46 finishing. From that, FDA concluded there is "a lack of evidence to make a conclusion on the effectiveness of BPC-157 for treating UC." Reviewers found no human pharmacokinetic data for the oral, nasal or transdermal routes at all. The one trial listed on ClinicalTrials.gov, a Phase 1 pilot in healthy volunteers, was last updated in December 2015 and has never posted results. FDA's adverse-event database returned three reports, each carrying confounders or missing detail that the agency said limited how far it could be read. And FDA flags immunogenicity as a live concern, meaning the risk that a peptide given as an injection provokes an immune response, amplified by aggregation and peptide-related impurities. That is the record a committee split 8–6 over, and on the strength of it BPC-157 carries no approval for human use from any government health authority.^{[5, 7, 8]}

How to check any peptide's status yourself

Two habits keep you out of trouble here. First, read the actual FDA page rather than a headline about it: the Category 2 page and the 503A compounding page each carry a "Content current as of" date, and a compound's row can move between tables without the agency shifting its safety view by an inch. Second, keep four questions separate instead of collapsing them into one word. Is the molecule a prescription drug under a brand name? May a pharmacy lawfully compound it? Is the research-use version lawful to sell for people? And is it prohibited in sport? For BPC-157 in late July 2026: it is not approved as a prescription medicine, a pharmacy still may not lawfully compound it, the research-use version is not lawful to sell for human use, and it is prohibited in sport. Our full scorecard of every peptide the July committee reviewed is at /learn/fda-peptide-list-2026; the per-compound status hub is at /learn/is-my-peptide-legal-2026; the general consumer picture is at /learn/are-peptides-legal; and the evidence write-up for this compound is at /verdicts/bpc-157.^{[1, 2, 3]}

References & sources

1. U.S. Food and Drug Administration — Category 2 of the Bulk Substances Nominated Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act (includes the "nominated but withdrawn" table listing BPC-157; content current as of 22 April 2026).
2. U.S. Food and Drug Administration — Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (interim-policy categories 1–3; notice-and-comment rulemaking for the 503A Bulks List; content current as of 14 May 2026).
3. U.S. Food and Drug Administration — July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (agenda, substances considered, and the use evaluated for each).
4. U.S. Food and Drug Administration — July 23–24, 2026 Pharmacy Compounding Advisory Committee: Questions (the verbatim voting questions put to the committee).
5. U.S. Food and Drug Administration — FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23–24, 2026: BPC-157-Related Bulk Drug Substances (BPC-157 free base and BPC-157 acetate).
6. U.S. Food and Drug Administration — Compounding and the FDA: Questions and Answers ("Compounded drugs are not FDA-approved").
7. World Anti-Doping Agency — The 2026 Prohibited List, in force 1 January 2026 (class S0, non-approved substances, names BPC-157).
8. ClinicalTrials.gov — NCT02637284: Phase I pilot study in healthy volunteers of PCO-02, active ingredient BPC-157 (last update posted December 2015; no results posted).